Previous news features


We have published the latest evidence for CFTR correctors such as lumacftor-ivacaftor (marketed as OrkambiTM) and tezacaftor-ivacaftor (marketed as SymdekoTM) in a new review now available to read here. We have included 13 randomised controlled trials with a total of 2215 people with cystic fibrosis of all ages. The review looks at both monotherapy and combination therapy and presents evidence for clinical benefits as well as potential harms. In this fast-moving field of research, new trials are frequently being published and we intend to update this review regularly to provide the cystic fibrosis population with the latest evidence base.

We have summarised our review in a podcast available here.

Jigsaw pieces


capsules on spoonWe have published an update of our review of hydroxyurea (hydroxycarbamide) for sickle cell diseaseThe latest version includes six new studies, bringing the total number of included studies to eight (almost 900 participants) lasting up to 30 months.


Professor Kevin Southern has recorded a podcast to accompany our new review 'Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis'. You can listen to the podcast here.


Dr with patientsCheck out our new podcast about improving knowledge of sickle cell disease and recognising its complications for patients and caregivers. Lead author Monika Asnani summarises the evidence she and her colleagues from the Caribbean Institute for Health Research at the University of the West Indies in Kingston, Jamaica found.

stack of papers

New Group Publication

Check out this new paper in PLOS ONE on the use and reporting of cross-over trials in Cochrane reviews - two of the authors are members of our editorial team.


Photo of Prof Kevin Southern

Congratulations to one of our cystic fibrosis editors, Professor Kevin Southern, who has been awarded a personal chair within the Institute of Translational Medicine at the University of Liverpool.


sparklersWe will be 20 years old on 01 September 2015!

You can see our Co-ordinating Editor summarise the findings of the updated review on antibioitic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis in his podcast below.


We would like to congratulate oneof our haemoglobinopathy editors, Dr Samir Ballas, Emeritus Professor of Medicine, Thomas Jefferson University who was selected as the 2015 recipient of the American Academy of Pain Medicine (AAPM) Patient Advocacy Award. The Patient Advocacy Award recognizes activity of an individual in advocating for appropriate evaluation and treatment of patients suffering from pain. This award was created to honor those healthcare professionals whose deeds reflect their recognition of the importance and impact of the specialty of Pain Medicine. The Academy recognizes only a few individuals for their outstanding contributions to the field of Pain Medicine each year. Dr. Ballas has been a long time advocate for excellent pain management in people with sickle cell disease.